DEST Destiny Pharma Plc

TIDMDEST

RNS Number : 7233Q

Destiny Pharma PLC

20 October 2023

Destiny Pharma plc

("Destiny Pharma" or the "Company")

Grant of Share Options

Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections, announces that it has granted options over a total of 3,053,532 new ordinary shares of GBP0.01 each in the Company ("Options") (representing 3.21 per cent. of the Company's issued share capital) to the below named Directors of the Company.

 
Name            Position            Performance         Total         Options      Ordinary        Ordinary 
                                        Options       Options         held as        Shares          Shares 
                                         issued          held    a percentage          held         held as 
                                          Under          post       of issued                  a percentage 
                                      2020 LTIP         issue   share capital                     of issued 
                                         Scheme                                               share capital 
                Chief Executive 
Chris Tovey      Officer              2,453,532     2,453,532           2.58%       40,000*           0.04% 
                Chief Financial 
Shaun Claydon    Officer                300,000     1,211,001           1.27%        24,286           0.03% 
William         Chief Scientific 
 Love            Officer                300,000     1,259,549           1.32%   6,509,500**           6.83% 
 

*10,000 of these Ordinary Shares are held by Chris Tovey and 30,000 are held by Chris Tovey's wife and two daughters

**1,017,700 of these Ordinary Shares are held by William Love and 5,491,800 are held by Carol Love

The above Options granted to the Directors represent awards under the Destiny Pharma plc 2020 Long Term Incentive Plan approved by the Company on 22 December 2020 for EMI and non-tax advantaged options (the "Employee LTIP 2020"). The Options, which represent awards to Shaun Claydon and William Love in relation to the year ended 31 December 2022 and to Chris Tovey pursuant to an agreed equity incentive award on joining the Company, have been granted with a nominal exercise price and will vest subject to the achievement of Total Shareholder Return targets over a three-year performance period. Following the grant of these Options, the Company will have in issue outstanding options representing approximately 11.3 per cent. of its issued share capital.

The Total Shareholder Return metrics will be fully laid out in the Company's report and accounts for the year to 31 December 2023.

For further information, please contact:

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

+44 (0) 127 370 4440

pressoffice@destinypharma.com

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Geoff Nash / George Dollemore, Corporate Finance

Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

Shore Capital (Joint Broker)

Daniel Bush / James Thomas / Lucy Bowden

+44 (0) 207 408 4090

Powerscourt Group

Sarah Macleod / Adam Michael / Ollie Simmonds / Christopher Ward

+44 (0) 20 7250 1446

Destiny@powerscourt-group.com

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.

For further information on the Company, please visit www.destinypharma.com

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the company's obligations under Article 17 of MAR

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 
1.  Details of the person discharging managerial responsibilities 
     / person closely associated 
a)  Name                            Chris Tovey 
2.  Reason for the Notification 
a)  Position/status                 Chief Executive Officer 
b)  Initial notification/Amendment  Initial notification 
3.  Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
a)  Name                            Destiny Pharma plc 
b)  LEI                             213800O9WH9Z38EHAC95 
4.  Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place where 
     transactions have been conducted 
a)  Description of the              Options over ordinary shares 
     Financial instrument,           of 1 pence each ("Ordinary 
     type of instrument              Shares") under the 2020 Destiny 
                                     Pharma plc Long Term Incentive 
                                     Plan. 
    Identification code             DEST GB00BDHSP575 
b)  Nature of the transaction       Grant of options over Ordinary 
                                     Shares under the 2020 Destiny 
                                     Pharma plc Long Term Incentive 
                                     Plan. 
c)  Price(s) and volume(s)          1 pence exercise price per 
                                     Ordinary Share 
                                     2,453,532 Ordinary Shares 
d)  Aggregated information: 
     Aggregated volume                See 4c) above 
     Price 
e)  Date of the transaction         18 October 2023 
f)  Place of the transaction        Outside of trading venue 
 
 
1.  Details of the person discharging managerial responsibilities 
     / person closely associated 
a)  Name                            Shaun Claydon 
2.  Reason for the Notification 
a)  Position/status                 Chief Financial Officer 
b)  Initial notification/Amendment  Initial notification 
3.  Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
a)  Name                            Destiny Pharma plc 
b)  LEI                             213800O9WH9Z38EHAC95 
4.  Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place where 
     transactions have been conducted 
a)  Description of the              Options over Ordinary Shares 
     Financial instrument,           under the 2020 Destiny Pharma 
     type of instrument              plc Long Term Incentive Plan. 
    Identification code             DEST GB00BDHSP575 
b)  Nature of the transaction       Grant of options over Ordinary 
                                     Shares under the 2020 Destiny 
                                     Pharma plc Long Term Incentive 
                                     Plan. 
c)  Price(s) and volume(s)          1 pence exercise price per 
                                     Ordinary Share 
                                     300,000 Ordinary Shares 
d)  Aggregated information: 
     Aggregated volume                See 4c) above 
     Price 
e)  Date of the transaction          18 October 2023 
f)  Place of the transaction        Outside of trading venue 
 
 
1.  Details of the person discharging managerial responsibilities 
     / person closely associated 
a)  Name                            William Love 
2.  Reason for the Notification 
a)  Position/status                 Chief Scientific Officer 
b)  Initial notification/Amendment  Initial notification 
3.  Details of the issuer, emission allowance market participant, 
     auction platform, auctioneer or auction monitor 
a)  Name                            Destiny Pharma plc 
b)  LEI                             213800O9WH9Z38EHAC95 
4.  Details of the transaction(s): section to be repeated 
     for (i) each type of instrument; (ii) each type of 
     transaction; (iii) each date; and (iv) each place where 
     transactions have been conducted 
a)  Description of the              Options over Ordinary Shares 
     Financial instrument,           under the 2020 Destiny Pharma 
     type of instrument              plc Long Term Incentive Plan. 
    Identification code             DEST GB00BDHSP575 
b)  Nature of the transaction       Grant of options over Ordinary 
                                     Shares under the 2020 Destiny 
                                     Pharma plc Long Term Incentive 
                                     Plan. 
c)  Price(s) and volume(s)          1 pence exercise price per 
                                     Ordinary Share 
                                     300,000 Ordinary Shares 
d)  Aggregated information: 
     Aggregated volume                See 4c) above 
     Price 
e)  Date of the transaction         18 October 2023 
f)  Place of the transaction        Outside of trading venue 
 

, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHMLBFTMTMBBBJ

(END) Dow Jones Newswires

October 20, 2023 02:04 ET (06:04 GMT)